Woodline Partners LP Verona Pharma PLC Transaction History

Woodline Partners LP

$11 Billion
Q3 2024

A detailed history of Woodline Partners LP transactions in Verona Pharma PLC stock. As of the latest transaction made, Woodline Partners LP holds 507,945 shares of VRNA stock, worth $18 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

507,945

Previous 501,198 1.35%

Holding current value

$18 Million

Previous $7.25 Million 101.64%

% of portfolio

0.13%

Previous 0.07%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$15.46 - $30.16 $104,308 - $203,489	6,747 Added 1.35%	507,945 $14.6 Million
Q2 2024 Aug 14, 2024	SELL	$11.48 - $17.02 $3.89 Million - $5.76 Million	-338,569 Reduced 40.32%	501,198 $7.25 Million
Q1 2024 May 15, 2024	BUY	$15.3 - $20.24 $5.18 Million - $6.86 Million	338,802 Added 67.63%	839,767 $13.5 Million
Q4 2023 Feb 14, 2024	SELL	$11.94 - $20.47 $1.02 Million - $1.76 Million	-85,757 Reduced 14.62%	500,965 $9.96 Million
Q3 2023 Nov 14, 2023	BUY	$16.3 - $22.09 $1.41 Million - $1.92 Million	86,722 Added 17.34%	586,722 $9.56 Million
Q2 2023 Aug 14, 2023	SELL	$19.41 - $23.43 $24.2 Million - $29.2 Million	-1,244,264 Reduced 71.33%	500,000 $10.6 Million
Q1 2023 May 15, 2023	BUY	$18.06 - $25.27 $27 Million - $37.8 Million	1,494,264 Added 597.71%	1,744,264 $35 Million
Q4 2022 Feb 14, 2023	SELL	$9.84 - $26.13 $1.23 Million - $3.27 Million	-125,033 Reduced 33.34%	250,000 $6.53 Million
Q3 2022 Nov 14, 2022	SELL	$4.14 - $13.59 $523,399 - $1.72 Million	-126,425 Reduced 25.21%	375,033 $3.83 Million
Q2 2022 Aug 15, 2022	BUY	$3.55 - $5.06 $1.78 Million - $2.54 Million	501,458 New	501,458 $2.1 Million

Others Institutions Holding VRNA

# of Institutions

160

Shares Held

68.4M

Call Options Held

667K

Put Options Held

643K

View Full List

About Verona Pharma plc

Ticker VRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,954,200
Market Cap $2.16B
Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...

More about VRNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account

Woodline Partners LP Verona Pharma PLC Transaction History